Drug Interactions between dofetilide and iohexol
This report displays the potential drug interactions for the following 2 drugs:
- dofetilide
- iohexol
Interactions between your drugs
iohexol dofetilide
Applies to: iohexol and dofetilide
MONITOR: The use of iodine-containing contrast media for coronary angiography in patients treated with certain antiarrhythmics such as amiodarone may result in significant prolongation of the QT interval. These contrast agents can be arrhythmogenic when injected into the coronary arteries and may have additive effects on cardiac repolarization when coadministered with antiarrhythmic agents that prolong the QT interval. In a retrospective study of patients who underwent cardiac catheterization at a German hospital, 21 patients who had been receiving long-term amiodarone therapy exhibited significantly increased QT interval 12 to 24 hours after catheterization compared to 21 age-matched controls who received cardiac catheterization without prior amiodarone or other QT prolonging treatment. In the amiodarone group, the QTc interval (i.e., QT interval corrected for heart rate) increased on average by 10% from 433 ms to 480 ms. QTc prolongation exceeding 500 ms did not occur in any of the amiodarone patients before catheterization but occurred in 6 patients after catheterization. No significant change was observed in the control group.
MANAGEMENT: Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.g., disopyramide, quinidine, procainamide) or class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents. Increased surveillance and ECG monitoring may be appropriate. Patients who receive outpatient angiographies should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of arrhythmia such as dizziness, palpitations, or syncope.
References (1)
- Goernig M, Kirmeier T, Krack A, Hartog CS, Figulla HR, Leder U (2004) "Iohexol contrast medium induces QT prolongation in amiodarone patients." Br J Clin Pharmacol, 58, p. 96-98
Drug and food interactions
dofetilide food
Applies to: dofetilide
In vitro data suggest that grapefruit juice may inhibit the CYP450 3A4 first-pass metabolism of dofetilide. Decreased first-pass metabolism may increase dofetilide concentrations and increase the risk of QT interval prolongation and arrhythmias. The clinical significance is unknown, since dofetilide has a high oral bioavailability and a low affinity for CYP450 3A4. The manufacturer recommends caution.
References (1)
- (2001) "Product Information. Tikosyn (dofetilide)." Pfizer U.S. Pharmaceuticals
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.